- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial | ||
| Fr | Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle | ||
| Fr | Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral | ||
| Do | Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure | ||
| Do | Pfizer adds to Seagen scrap heap with another early cancer candidate cull | ||
| Do | Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector | ||
| Do | Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals | ||
| Mi | Rare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and Congress | ||
| Mi | Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome | ||
| Mi | Crossbow hits $77M series B round to bankroll quiver of T-Bolts | ||
| Di | Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for' | ||
| Di | J&J changes New York state of mind, closing JLABS site after 8 years | ||
| Di | Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30% | ||
| Di | FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings | ||
| Di | Pfizer's hotly tipped breast cancer prospect delivers phase 2 win | ||
| Mo | Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development | ||
| Mo | Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years | ||
| Mo | Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet | ||
| 13.03. | Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient | ||
| 13.03. | Inovio trims team as trouble brews at FDA for rare disease candidate | ||
| 13.03. | Immutep's phase 3 failure for immunotherapy surprises analysts, sinks stock | ||
| 12.03. | Stop Asking for an AI strategy: 3 questions clinical leaders should ask instead | ||
| 12.03. | Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out | ||
| 12.03. | Vistagen lays off 20% of staff to tighten focus on struggling social anxiety candidate | ||
| 12.03. | Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.